Salix Recent News
Mizuho Isn't Convinced In Valeant's Turnaround, Cuts Price Target To $11
Report: Valeant Rejected A Takeover Offer Prior To Hiring Papa As CEO
Report: Valeant More Likely To Sell Drugs Than Business Units
Report: Valeant Has Tapped Investment Bankers To Help Review Strategic Options
Valeant Has Risk Of New Undisclosed SEC Probe, Report Says
SEC Investigating Ex-Salix Executives Over Misleading Investors
Unleash The Bulls: Surge In September Hiring Data Jolts Markets Higher
Piper Jaffray Tidbits From Salix Management
Salix Pharmaceuticals Initiated At Neutral
Salix Expecting $1B In Sales For Xifaxan